Hahn's performance is causing alarm
Beyond what the FDA’s plasma decision means for public health, it provided the first major prime-time exposure for rookie Commissioner Stephen Hahn, and his performance has agency watchers worried for the future.
As STAT’s Nicholas Florko and Lev Facher, Hahn is a decorated physician but a political novice, and he’s running the FDA at a time when the typically nonpartisan questions of safety and efficacy carry sweeping electoral importance. His closest advisers are an insular group of people with little experience with agency leadership, and he hasn’t sought the advice of past commissioners.
That has FDA experts concerned about whether Hahn is prepared for the mounting pressure on his agency. And Sunday’s display, in which Hahn misrepresented the data behind convalescent plasma for Covid-19, isn’t engendering much faith.
Read more.
As STAT’s Nicholas Florko and Lev Facher, Hahn is a decorated physician but a political novice, and he’s running the FDA at a time when the typically nonpartisan questions of safety and efficacy carry sweeping electoral importance. His closest advisers are an insular group of people with little experience with agency leadership, and he hasn’t sought the advice of past commissioners.
That has FDA experts concerned about whether Hahn is prepared for the mounting pressure on his agency. And Sunday’s display, in which Hahn misrepresented the data behind convalescent plasma for Covid-19, isn’t engendering much faith.
Read more.
.png)
No hay comentarios:
Publicar un comentario